iShares U.S. Healthcare ETF IYH
77.66 USD +0.03 (+0.04%)
Nov 6, 2026, 2:06 PM EST
76.06 Day range 77.93
59.63 52-week range 80.71
- YTD
- +19.29%
- 1 year
- +26.54%
- Market cap
- 4.74B
- EPS (ttm)
- 2.59
- P/E ratio
- 30.01
- YTD return
- +19.29%
- 1-year return
- +26.54%
- Volume
- 326.85K
- Avg volume
- 829.72K
- Open
- 76.21
- Previous close
- 77.63
- Day's range
- 76.06 – 77.93
- 52-week range
- 59.63 – 80.71
YTD +12.35 (+18.90%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 72.87
- 200-day average
- 66.87
Next earnings
Consensus EPS estimate 0.00.
About iShares U.S. Healthcare ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index. The underlying index measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.
News
Kalshi, Polymarket Put Democrats' Senate Odds At More Than 70%: 5 ETFs That Could Move If They're Wrong 
Target, Truist Financial And More On CNBC’s ‘Final Trades’ 
J.B. Hunt Transport, LPL Financial And More On CNBC’s ‘Final Trades’ 
Justin Wolfers Warns of a 'Pink Collar' Economy Amid July Jobs Report: 'If You Don't Wear Scrubs… You're Losing Jobs' 
Apple, Micron, Rocket Companies And More On CNBC’s ‘Final Trades’ 
UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses 
White House Reportedly Preparing To Oust FDA Commissioner Marty Makary 
Okta, Phillips 66 And More: CNBC's 'Final Trades' 
AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss 
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
Your note
Sign in to keep a note on IYH — it syncs with the Stock Master app.